Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

Authors :: Giovanni Di Perri
Giuliano Rizzardini
Cacopardo Bruno
Giustino Parruti
Anna Maria Cattelan
Antonio Di Biagio
Hamid Hasson
Laura Milazzoi
Antonio Chirianni
Caterina Pasquazzi
Vincenzo Vullo
Massimo Puoti
Claudio Maria Mastroianni
Nicola Boffa
Alfredo Pennica
Gloria Taliani
Simit
Loredana Sarmati
Angiola Spinetti
Andrea Antinori
Antonella d'Arminio Monforte
Savatore Sollima
Andrea De Luca
D. Segala
Sara Bigoni
Raffaele Bruno
Vanni Borghi
Elisabetta Teti
Annalisa Saracino
Andrea Gori
Andreoni Massimo
Andrea Giacometti
Massimo, A
Teti, E
Antinori, A
Milazzoi, L
Sollima, S
Rizzardini, G
Di Biagio, A
Saracino, A
Bruno, R
Borghi, V
DE LUCA, A
Cattelan, A
Hasson, H
Taliani, G
Monforte, A
Mastroianni, C
Di Perri, G
Bigoni, S
Puoti, M
Spinetti, A
Gori, A
Boffa, N
Bruno, C
Giacometti, A
Parruti, G
Vullo, V
Chirianni, A
Pennica, A
Pasquazzi, C
Segala, D
Sarmati, L
Publication Year :: 2017
Publisher :: Oxford University Press, 2017.
Abstract: Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

Tools